EMBC

Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.

Wall Street analysts forecast EMBC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EMBC is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Embecta Corp revenue for the last quarter amounts to 264.00M USD, decreased -7.72 % YoY.

Embecta Corp. EPS for the last quarter amounts to 0.44 USD, increased 76.00 % YoY.

Embecta Corp (EMBC) has 1850 emplpoyees as of December 16 2025.

Today EMBC has the market capitalization of 698.06M USD.